The period in brief – financial summary for the second quarter 2024

• Net sales amounted to SEK 0 million (SEK 0 million).
• R&D expenses amounted to SEK 9,7 million (SEK 16,5 million).
• Operating loss for the quarter amounted to SEK –11,4 million (SEK -18,3 million).
• Loss after financial items for the quarter amounted to SEK –10,9 million (SEK -18,2 million).
• Basic and diluted earnings per share for the quarter amounted to SEK –0,09 (SEK -0,23).
• Cash flow from operating activities for the quarter amounted to SEK –14,4 million (SEK -14,8 million).
• Equity on June 30, 2024 amounted to SEK 83,0 million (SEK 76,9 million) or SEK 0,68 (SEK 0,94) per share.
• The equity/assets ratio on June 30, 2024 was 87 percent (84 percent).
• Cash and cash equivalents on June 30, 2024 amounted to SEK 75,7 million (SEK 67,0 million).

Financial summary for the full period January 1-June 30 2024

• Net sales amounted to SEK 0 million (SEK 0 million).
• R&D expenses amounted to SEK 21,2 million (SEK 31,7 million).
• Operating loss for the quarter amounted to SEK –24,7 million (SEK -35,5 million).
• Loss after financial items for the quarter amounted to SEK –23,9 million (SEK -35,7 million).
• Basic and diluted earnings per share for the quarter amounted to SEK –0,22 (SEK -0,45).
• Cash flow from operating activities amounted to SEK –29,1 million (SEK -33,8 million).
• Equity on June 30, 2024 amounted to SEK 83,0 million (SEK 76,9 million) or SEK 0,68 (SEK 0,94) per share.
• The equity/assets ratio on June 30, 2024 was 87 percent (84 percent).
• Cash and cash equivalents on June 30, 2024 amounted to SEK 75,7 million (SEK 67,0 million).

Significant events during the second quarter 2024

• Kancera reported positive top line results from the KAND145 phase I study in healthy subjects and that the study met its primary objectives.
• Kancera reported that Robert Edfors has been appointed new Chief Scientific Officer and Senior Vice President Clinical Development as from September 1 and that Johan Schultz, Vice President R&D Operations and Maria Sahlberg, Vice President Regulatory Affairs and Compliance have been added to the executive management team.
• The Annual General Meeting decided for re-election of the chairman of the board and all board members and new election of BDO Mälardalen AB as financial auditor.
• The company’s candidate drugs KAND567 and KAND145 have been granted International Non-proprietary Names (INN) by WHO.

Significant events after the end of the period

• Kancera has reported that part one of the KANDOVA study, phase Ib, has been successfully completed and that phase IIa has started.

About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of inflammation and cancer through its candidate drugs KAND567 and KAND145. Kancera’s candidate drugs are targeting the fractalkine axis, which controls specific disease promoting immune cells with high precision. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information
Please refer the presentation of the 2024 Q2 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/

or contact:
ir@kancera.com or phone: +46 (0)8-5012 60 80